BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34511122)

  • 1. LncRNA HOXA-AS2 regulates microglial polarization via recruitment of PRC2 and epigenetic modification of PGC-1α expression.
    Yang X; Zhang Y; Chen Y; He X; Qian Y; Xu S; Gao C; Mo C; Chen S; Xiao Q
    J Neuroinflammation; 2021 Sep; 18(1):197. PubMed ID: 34511122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isovitexin-Mediated Regulation of Microglial Polarization in Lipopolysaccharide-Induced Neuroinflammation via Activation of the CaMKKβ/AMPK-PGC-1α Signaling Axis.
    Liu B; Huang B; Hu G; He D; Li Y; Ran X; Du J; Fu S; Liu D
    Front Immunol; 2019; 10():2650. PubMed ID: 31798583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression.
    Xie M; Sun M; Zhu YN; Xia R; Liu YW; Ding J; Ma HW; He XZ; Zhang ZH; Liu ZJ; Liu XH; De W
    Oncotarget; 2015 Oct; 6(32):33587-601. PubMed ID: 26384350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury.
    Yang X; Xu S; Qian Y; Xiao Q
    Brain Behav Immun; 2017 Aug; 64():162-172. PubMed ID: 28268115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA HOXA-AS2 Promotes Oral Squamous Cell Proliferation, Migration, and Invasion via Upregulating EZH2 as an Oncogene.
    Zhao Z; Xing Y; Yang F; Zhao Z; Shen Y; Song J; Jing S
    Technol Cancer Res Treat; 2021; 20():15330338211039109. PubMed ID: 34519570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA HOXA-AS2 promotes the expression levels of hypoxia-inducible factor-1α and programmed death-ligand 1, and regulates nasopharyngeal carcinoma progression via miR-519.
    Wang S; You H; Yu S
    Oncol Lett; 2020 Nov; 20(5):245. PubMed ID: 32973958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML).
    Feng Y; Hu S; Li L; Peng X; Chen F
    Cell Death Dis; 2020 Dec; 11(12):1025. PubMed ID: 33268767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray Analysis of Long Non-Coding RNAs in Lung Tissues of Patients with COPD and HOXA-AS2 Promotes HPMECs Proliferation via Notch1.
    Zhou AY; Zhao YY; Zhou ZJ; Duan JX; Zhu YZ; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2449-2460. PubMed ID: 33116460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis.
    Dong X; Fang Z; Yu M; Zhang L; Xiao R; Li X; Pan G; Liu J
    Cell Physiol Biochem; 2018; 51(2):886-896. PubMed ID: 30466095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol Attenuated Manganese-Induced Learning and Memory Impairments in Mice Through PGC-1Alpha-Mediated Autophagy and Microglial M1/M2 Polarization.
    Lang J; Gao L; Wu J; Meng J; Gao X; Ma H; Yan D
    Neurochem Res; 2022 Nov; 47(11):3414-3427. PubMed ID: 35871432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
    Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
    Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naringenin promoted spinal microglia M2 polarization in rat model of cancer-induced bone pain via regulating AMPK/PGC-1α signaling axis.
    Ge MM; Li DY; Wang L; Zhang LQ; Liu DQ; Tian YK; Ye DW; Liu ZH; Zhou YQ; Yang H
    Biomed Pharmacother; 2022 May; 149():112912. PubMed ID: 35856853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
    Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia.
    Qu Y; Wang Y; Wang P; Lin N; Yan X; Li Y
    Cell Biol Int; 2020 Aug; 44(8):1745-1759. PubMed ID: 32369230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of long non-coding RNA HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition in gallbladder carcinoma.
    Zhang P; Cao P; Zhu X; Pan M; Zhong K; He R; Li Y; Jiao X; Gao Y
    Oncotarget; 2017 May; 8(20):33137-33143. PubMed ID: 28388535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1B/SUB1-activated lncRNA HOXA-AS2 drives the malignant behaviour of hepatoblastoma through regulation of HOXA3.
    Liu G; Liu B; Liu X; Xie L; He J; Zhang J; Dong R; Ma D; Dong K; Ye M
    J Cell Mol Med; 2021 Apr; 25(7):3524-3536. PubMed ID: 33683826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis.
    Xiao S; Song B
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32519740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA HOXA-AS2 Promotes Tumor Progression by Suppressing miR-567 Expression in Oral Squamous Cell Carcinoma.
    Chen R; Wang X; Zhou S; Zeng Z
    Cancer Manag Res; 2021; 13():5443-5455. PubMed ID: 34267554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Non-Coding RNA HOXA-AS2 Enhances The Malignant Biological Behaviors In Glioma By Epigenetically Regulating RND3 Expression.
    Wu L; Zhu X; Song Z; Chen D; Guo M; Liang J; Ding D; Wang W; Yan D
    Onco Targets Ther; 2019; 12():9407-9419. PubMed ID: 31819475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.